News Releases

Date Title and Summary
Toggle Summary Juno Therapeutics to Report Third Quarter 2017 Financial Results on Wednesday, November 1
SEATTLE --(BUSINESS WIRE)--Oct. 25, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO) will announce financial results for the third quarter 2017 on Wednesday, November 1, 2017 , after the close of U.S.-based financial markets. Following the announcement, Juno management will host a conference call and
Toggle Summary Juno Therapeutics Closes Follow-on Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
SEATTLE --(BUSINESS WIRE)--Sep. 26, 2017-- Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the closing of its follow-on public offering of 7,015,000 shares of its common stock at a price
Toggle Summary Juno Therapeutics Prices $250 Million Follow-on Offering
SEATTLE --(BUSINESS WIRE)--Sep. 21, 2017-- Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the pricing of its follow-on public offering of 6,100,000 shares of its common stock at a price
Toggle Summary Juno Therapeutics Opens New Headquarters and Research Center
Opening celebration and ribbon-cutting highlight advancements in cell therapy and Juno’s investment in scientific advancement SEATTLE --(BUSINESS WIRE)--Sep. 21, 2017-- Juno Therapeutics , Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the
Toggle Summary Juno Therapeutics Launches Follow-on Offering
SEATTLE --(BUSINESS WIRE)--Sep. 20, 2017-- Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the launch of a proposed follow-on public offering of $225 million of shares of its common stock.
Toggle Summary Juno Therapeutics to Present at September 2017 Investor Conferences
SEATTLE --(BUSINESS WIRE)--Aug. 31, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentations at two investor conferences in September. The presentations will feature a business overview and update by Steve Harr , Juno’s Chief Financial Officer and Head of
Toggle Summary Juno Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference
SEATTLE --(BUSINESS WIRE)--Aug. 8, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentation at the 2017 Wedbush PacGrow Healthcare Conference at 3:40 p.m. ET on Tuesday, August 15, 2017 . The presentation will feature a business overview and update by
Toggle Summary Juno Therapeutics Reports Second Quarter 2017 Financial Results
- Presented promising JCAR017 data in NHL with 66% (21/32) overall response and 50% (16/32) complete response at three months in core group moving to pivotal trial - - 2% (1/44) experienced severe CRS and 18% (8/44) experienced severe NT - - Completed JCAR017 commercial manufacturing process lock -
Toggle Summary Juno Therapeutics to Report Second Quarter 2017 Financial Results on Thursday, August 3
SEATTLE --(BUSINESS WIRE)--Jul. 27, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO) will announce financial results for the second quarter 2017 on Thursday, August 3, 2017 , after the close of U.S.-based financial markets. Following the announcement, Juno management will host a conference call and
Toggle Summary Juno Therapeutics Presents TRANSCEND NHL 001 Trial Data at International Conference on Malignant Lymphoma
– 66% (21/32) overall response and 50% (16/32) complete response at three months in core group moving to pivotal trial; of those patients in response at three months, 90% (9/10) continue in response at six months – 66% (29/44) of patients experienced no cytokine release syndrome or neurotoxicity in